Loading company…
Slate Medicines is developing PACAP-targeting therapeutics for migraine and headache disorders.
Slate Medicines develops therapies targeting PACAP for migraine and other headache disorders. Its lead program, SLTE-1009, is intended to advance into Phase 1 clinical trials, with additional therapies also in development. Based in Raleigh, US, the company is expected to receive USD 130.00 mn in connection with a merger transaction announced in August 2026.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in